BELINOSTAT AND ITS METABOLITES (INCLUDING BELINOSTAT GLUCURONIDE, BELINOSTAT AMIDE, METHYL BELINOSTAT) INHIBITED METABOLIC ACTIVITIES OF CYP2C8 AND CYP2C9. OTHER METABOLITES (3-ASBA AND BELINOSTAT ACID) INHIBITED CYP2C8.
IN CANCER PATIENTS, CO-ADMINISTRATION OF BELEODAQ (1,000 MG/MΒ²) AND WARFARIN (5 MG), A KNOWN CYP2C9 SUBSTRATE, DID NOT INCREASE THE AUC OR CMAX OF EITHER R-OR S-WARFARIN.